Quantum Discovery
Quantum Discovery Labs is a technology based drug discovery company. We develop a unique computational drug discovery platform (QUANTUM), provide drug discovery services, and pursue our own in-house drug discovery projects searching for novel compounds with anti-bacterial, anti-viral and anti-cancer efficacy.
Quantum@linkedin.com
Contacts: office@q-pharm.com or comment any post on the site. You are welcome!
Quantum on Google+Categories
- absorbtion (3)
- active transport (2)
- ADME (4)
- antibiotics (2)
- antiviral (6)
- bioavailability (3)
- cancer (5)
- cardiotoxicity (1)
- collaboration (13)
- compound libraries (1)
- COPD (1)
- docking (13)
- drug design (8)
- drug discovery platform (1)
- druglikeness (4)
- false positive (3)
- flue (4)
- Generalized Born (15)
- GPCR (1)
- HERG (6)
- HIV (3)
- HIV-1 integrase (1)
- HSV (1)
- human neutrophil elastase (1)
- IC50 (18)
- inflammation (3)
- influenza (3)
- kinase (1)
- LD50 (2)
- logP (1)
- matrix proteins (2)
- mechanism of action exploration (2)
- MRDD (3)
- new therapeutic uses (1)
- oncology (4)
- openbabel (3)
- PDK1 (1)
- polar liquid (17)
- publications (12)
- q-Mol (1)
- QSAR (1)
- Quantum Software (11)
- RecA (1)
- scoring (1)
- selectivity (3)
- solvation energy (19)
- ss DNA (1)
- talk (5)
- toxicity (7)
- trombine (2)
- tuberculosis (4)
- Uncategorized (5)
- video (3)
- water (20)
Recent comments
- Vladimir Chupakhin on Solubility in water/DMSO prediction
- Nbarnes25 on Quantum Discovery Services
- New MA/p17 matrix protein inhibitors display broad antiviral activity against multiple subtypes of HIV-1 on Influenza matrix M1 protein inhibitors show promising in-vivo efficacy
- Anonymous on Water polarization and density profiles at a gas-liquid interface
- Anonymous on New inhibitors of RecA (bacterial SOS response system) identified.
Uncategorized Archive
-
MA/p17 HIV matrix protein is a promising target for drug discovery
Posted on December 20, 2011 | No CommentsAs a result of the analysis of HIV virus targets, the most conservative among all the possible HIV-1 virus target protein—p17/MA (see figure)—was selected. This is a matrix (structural) protein,... -
2008 Quantum’s technology platform update and software releases
Posted on November 25, 2008 | No CommentsIt has been an exciting year here in Quantum Pharmaceuticals, another great year for our highly effective small molecule drug discovery and ADMET platform development. Our work is firmly based... -
Quantum Science Overview, v 0.1 has been released
Posted on September 19, 2007 | No CommentsQuantum Pharmaceuticals is pleased to release Quantum Science Overview. The document conveys an overview Quantum’s drug discovery solutions and scientific results. The content of the report are summarized below:I. A... -
Molecular dynamics of HIV Integrase with an inhibitor
Posted on January 9, 2007 | No CommentsBelow we provide an example of Molecular Dynamics of HIV-integrase monomer with 1- (5- CHLOROINDOL-3- YL)-3 -HYDROXY-3 -(2H- TETRAZOL- 5- YL)-PROPENONE (pdb code 1qs4). The protein structure is taken from... -
Protein flexibilty and ligand interaction complementarity example
Posted on December 10, 2006 | No CommentsHuman neutrophil elastase complexed with an inhibitor (gw475151) studied with QUANTUM normal modes analysis tools. The video shows the inhibitor (red licorice) remains in a strongly interacting position regardless of...
